BCAX Stock Analysis: Buy, Sell, or Hold?
BCAX - Bicara Therapeutics Inc. Common Stock
$23.90
-0.49 (-2.01%)
▼
5d:
-1.57%
30d:
-13.81%
90d:
+14.68%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When BCAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BCAX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BCAX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCAX is currently trading at $23.90, which is considered oversold relative to its 30-day fair value range of $24.79 to $27.71.
Technical Outlook: Technically, BCAX is in a strong uptrend. Immediate support is located at $22.80, while resistance sits at $28.40.
Market Sentiment: BCAX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.50 (+40.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCAX is in a strong uptrend. Immediate support is located at $22.80, while resistance sits at $28.40.
Market Sentiment: BCAX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.50 (+40.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.79 -
$27.71
Company Quality Score
52/100
(HOLD)
Options IV Signal
3th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 3th percentile)
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.2% below Wall St target ($33.50)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.79 -
$27.71
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.95
(12.3%)
Support & Resistance Levels
Support Level
$22.80
Resistance Level
$28.40
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.91
Wall Street Target
$33.50
(+40.2%)
Share & Embed Analysis
Last updated: August 24, 2026 8:26 AM ET
Data refreshes hourly during market hours. Next update: 9:26 AM
Data refreshes hourly during market hours. Next update: 9:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
17
Sells
Net
INSIDERS SELLING
Recent Transactions
Ivan Hyep
SELL
9200 shares
2026-04-21
Claire Mazumdar
SELL
15000 shares
2026-04-20
Ryan Cohlhepp
SELL
12500 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
